What is Innate Pharma S.A. (IPHYF) stock price today?

Innate Pharma S.A. (IPHYF) is currently trading at $1.65, up 0% today.

What is IPHYF P/E ratio?

Innate Pharma S.A.'s P/E ratio is -2.84. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is IPHYF return on equity (ROE)?

Innate Pharma S.A.'s return on equity (ROE) is 593.93%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Innate Pharma S.A.'s market cap?

Innate Pharma S.A. has a market capitalization of $154.94M.

OTC · Biotechnology

Innate Pharma S.A. (IPHYF) Stock

$1.65 +0.00% OTC: IPHYF Healthcare

Valuation

Metric	Value
Price	$1.65
Market Cap	$154.94M
P/E Ratio	-2.84
P/B Ratio	-6.58
P/S Ratio	52.63
EPS (TTM)	$-0.55
52-Week High	$2.25
52-Week Low	$1.31
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	593.93%
ROA	-78.41%
ROCE	-220.01%
Gross Margin	100.00%
Operating Margin	-1766.67%
Net Margin	-1633.33%
Debt/Equity	-1.04
Current Ratio	1.27

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$12.0M	$50.0M	$62.0M	$13.0M	$3.0M
Operating Profit	$-48.0M	$-57.0M	$-13.0M	$-52.0M	$-53.0M
Net Profit	$-53.0M	$-58.0M	$-8.0M	$-49.0M	$-49.0M
EPS	$-0.57	$-0.73	$-0.09	$-0.61	$-0.55
Op Margin	-394.9%	-115.7%	-20.6%	-408.6%	-1917.7%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$267.0M	$208.0M	$175.0M	$111.0M	$63.0M
Total Liabilities	$160.0M	$154.0M	$132.0M	$102.0M	$84.0M
Cash	$104.0M	$84.0M	$71.0M	$66.0M	$28.0M
Borrowings	$44.0M	$42.0M	$40.0M	$31.0M	$23.0M

Latest News

Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference Business Wire · Jul 23, 2026 Innate Pharma Closes Enrollment in Phase 1 Advanced Solid Tumors Study MT Newswires · Jul 21, 2026 Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) Business Wire · Jul 21, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-58.0M	$-19.0M	$-33.0M	$-7.0M	$-53.0M
Investing Cash Flow	$-2.0M	$1.0M	$18.0M	$9.0M	$7.0M
Financing Cash Flow	$0	$0	$0	$3.0M	$-7.0M
Net Cash Flow	$-33.0M	$-20.0M	$-14.0M	$-4.0M	$-30.0M
Free Cash Flow	$-60.0M	$-20.0M	$-35.0M	$-7.0M	$-53.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.29
EV / EBITDA	-2.52
FCF Yield	-36.06%
Quick Ratio	1.27
Interest Coverage	-18.38
Return 1Y	25.95%
Return 3Y	-44.82%
Return 5Y	-47.62%

Ownership

Insiders Held20.77%

Institutions Held10.06%

Institutions Float Held12.69%

Institutional Holder	Shares	Report Date
Dimensional ETF Trust-Dimensional International Small Cap ETF	23,277	2026-01-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About Innate Pharma S.A.

Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor that has progressed to Phase III clinical trials, being investigated for its potential in treating advanced solid tumors, notably colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1. This compound is in Phase II clinical assessment for a range of inflammatory conditions, including COVID-19, bullous pemphigoid, and chronic spontaneous urticaria. IPH5201: A blocking antibody in Phase I trials, aimed at the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody targeting the immunosuppressive adenosine pathway to enhance anti-tumor immunity. IPH6101: An NKp46-based NK cell engager, intended for the development and assessment of up to two bispecific NK cell engagers. Beyond its clinical programs, Innate Pharma maintains an active preclinical research effort, featuring candidates such as IPH43 (an anti-MICA/B antibody-drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. To support its development and market reach, Innate Pharma has established strategic alliances and licensing agreements with major pharmaceutical companies, including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Additionally, it holds a co-development and license agreement with MedImmune Limited. The company was founded in 1999 and continues to operate from its headquarters in Marseille, France.

Innate Pharma S.A. is headquartered in FR.

Innate Pharma S.A. (IPHYF) stock trades at $1.65 with a market capitalization of $154.94M. The stock is valued at a price-to-earnings (P/E) ratio of -2.84, price-to-book of -6.58, price-to-sales of 52.63. Over the past 52 weeks the stock has ranged between $1.31 and $2.25, and currently trades 26.7% below its 52-week high.

On profitability, Innate Pharma S.A. generates a return on equity (ROE) of 593.93% — well above the market average, a sign of a high-quality business, return on capital employed of -220.01%, an operating margin of -1766.67%, a net profit margin of -1633.33%.

Official website: www.innate-pharma.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides